Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
and drawing on his extensive commercial leadership experience at Insmed, Shire, and AstraZeneca. Adsett's background in building global commercial organizations and guiding major drug launches aligns closely with Definium's late-stage pipeline, including its FDA Breakthrough Therapy–designated candidate DT120 ODT for generalized anxiety disorder. We'll now examine how Adsett's appointment to the board shapes Definium Therapeutics' investment narrative as its late-stage pipeline advances. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. To own Definium Therapeutics, you have to believe that its late-stage psychedelic-derived pipeline, especially DT120 ODT in generalized anxiety disorder and major depressive disorder, can progress from clinical promise to a real commercial franchise despite zero current revenue and ongoing lo
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business UpdatesBusiness Wire
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- DFTX's page on the SEC website